Reviva Pharmaceuticals Announced Preclinical Efficacy Data on Brilaroxazine in IPF at the 2023 American Thoracic Society International Conference and Publication in Medical Research Archives

25.05.2023 - Brilaroxazine, a novel serotonin-dopamine modulator with multifaceted activities has the potential to treat idiopathic pulmonary fibrosis (IPF) Brilaroxazine improved survival and lung function, and reduced lung fibrosis and inflammation in a ... Seite 1

Related Keywords

Washington ,United States ,American ,Pirfenidone Esbriet ,Nintedanib Ofev ,Reviva Pharmaceuticals Holdings Inc ,International Conference ,Drug Administration ,American Thoracic Society ,Research Archives ,Nasdaq ,Orphan Drug Designation ,Pharmaceuticals Holdings ,Thoracic Society ,Medical Research ,Laxminarayan Bhat ,